SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence

Sodium-glucose cotransporter-2 (SGLT2) inhibitors may offer clinically meaningful reductions in atrial fibrillation (AF) risk and recurrence, and outperform glucagon-like peptide-1 (GLP-1) receptor agonists in reducing heart failure.

Evidence…